Published in Antimicrob Agents Chemother on April 01, 2000
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother (2004) 2.96
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother (2003) 2.92
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol (2005) 2.32
In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother (2003) 2.03
In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother (2002) 1.92
Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol (2003) 1.75
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2007) 1.61
Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev (2004) 1.60
Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother (2001) 1.49
Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans. Antimicrob Agents Chemother (2011) 1.45
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother (2001) 1.45
Current perspectives on echinocandin class drugs. Future Microbiol (2011) 1.44
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother (2001) 1.34
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2008) 1.28
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 1.25
Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis (2004) 1.23
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother (2004) 1.13
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob Agents Chemother (2006) 0.98
Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother (2009) 0.98
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2013) 0.96
Occidiofungin's chemical stability and in vitro potency against Candida species. Antimicrob Agents Chemother (2011) 0.90
Method for measuring postantifungal effect in Aspergillus species. Antimicrob Agents Chemother (2002) 0.90
Differential antifungal activity of isomeric forms of nystatin. Antimicrob Agents Chemother (2001) 0.87
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. Braz J Microbiol (2009) 0.81
Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob Agents Chemother (2006) 0.79
Sublethal injury and resuscitation of Candida albicans after amphotericin B treatment. Antimicrob Agents Chemother (2003) 0.79
Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother (2012) 0.78
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. J Clin Microbiol (2010) 0.77
Advances in the treatment of invasive neonatal candidiasis. Expert Opin Pharmacother (2015) 0.76
Anidulafungin and its role in candida infections. Infect Drug Resist (2009) 0.75
In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran. Jundishapur J Microbiol (2015) 0.75
Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. PLoS One (2015) 0.75
Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection. Eur J Drug Metab Pharmacokinet (2013) 0.75
Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. Antimicrob Agents Chemother (2015) 0.75
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis (1997) 2.70
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis (1999) 2.57
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother (1998) 2.43
The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother (1994) 1.82
Growth medium effect on the antifungal activity of LY 303366. Diagn Microbiol Infect Dis (1997) 1.65
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother (1998) 1.64
Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother (1998) 1.60
Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J Antimicrob Chemother (1994) 1.01
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med (1988) 6.78
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med (1992) 5.28
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis (1995) 4.36
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med (1989) 4.23
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother (2000) 4.12
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis (1999) 3.92
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol (1994) 3.77
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother (1994) 3.59
Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis (1986) 3.51
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol (2002) 3.30
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med (1991) 3.24
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med (1989) 2.97
Clinical laboratory comparison of a slide blood culture system with a conventional broth system. J Clin Microbiol (1982) 2.95
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 2.89
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.77
Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol (1990) 2.72
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis (1997) 2.70
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis (1998) 2.67
A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei. N Engl J Med (1994) 2.61
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis (1999) 2.61
Comparison of the Septi-Chek AFB and BACTEC systems and conventional culture for recovery of mycobacteria. J Clin Microbiol (1993) 2.58
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis (1999) 2.57
The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. Clin Infect Dis (1996) 2.52
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother (1998) 2.43
Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med (1991) 2.33
Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother (2002) 2.33
Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol (2002) 2.29
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother (1991) 2.26
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis (2000) 2.22
Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol (1994) 2.22
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother (1998) 2.18
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA (1991) 2.07
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis (1998) 2.04
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Laboratory evaluation of leukocyte esterase and nitrite tests for the detection of bacteriuria. J Clin Microbiol (1985) 1.99
Comparison of the Quantum II Bacterial Identification System and the AutoMicrobic System for the identification of gram-negative bacilli. J Clin Microbiol (1986) 1.98
Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol (1999) 1.98
Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis (1998) 1.96
Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. J Clin Microbiol (1999) 1.96
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis (1997) 1.95
Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol (1994) 1.91
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis (2001) 1.91
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
Clinical laboratory evaluation of a urine screening device. J Clin Microbiol (1983) 1.83
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents (2000) 1.83
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob Agents Chemother (1999) 1.75
Standardization of antifungal susceptibility testing. J Antimicrob Chemother (1996) 1.73
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother (2002) 1.70
Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother (1999) 1.70
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 1.70
The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. Am J Health Syst Pharm (1999) 1.69
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis (2001) 1.68
Development and verification of fingerprinting probes for Candida glabrata. Microbiology (1997) 1.67
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. J Infect Dis (1996) 1.67
Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis (2002) 1.67
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother (2001) 1.66
Growth medium effect on the antifungal activity of LY 303366. Diagn Microbiol Infect Dis (1997) 1.65
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother (1998) 1.64
Molecular epidemiology for local outbreaks of methicillin resistant Staphylococcus aureus (MRSA). The need for several methods. Eur J Epidemiol (1994) 1.62
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2007) 1.61
Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother (1998) 1.60
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol (2009) 1.60
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.59
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA (1989) 1.59
Implications of acquired oxacillin resistance in the management and control of Staphylococcus aureus infections. J Infect Dis (1988) 1.59
Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J Clin Microbiol (1997) 1.56
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Eur J Clin Microbiol Infect Dis (1990) 1.56
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother (2000) 1.56
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.55
Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis (1993) 1.54
Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems. J Clin Microbiol (1999) 1.54
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol (2000) 1.53
Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern Med (1988) 1.51
Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother (1989) 1.50
Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis (1999) 1.50